The effects of gestation dating on the calculation of patient-specific risks in Down's syndrome screening: Multivariate case

Annals of Clinical Biochemistry

Volumn 34, Issue 1, 1997, Pages 55-60

  Bishop, J C ^a   Dunstan, F D J ^b   Nix, A B J ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Alpha fetoprotein; Human chorionic gonadotrophin

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN;

ARTICLE; DOWN SYNDROME; FEMALE; FETUS; GESTATIONAL AGE; HUMAN; LABORATORY TEST; MULTIVARIATE ANALYSIS; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031013837     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329703400108     Document Type: Article

References (14)

1. UK collaborative study of alpha-fetoprotein in relation to neural tube defects. Maternal serum alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancet 1977; i: 1323-32
2. Greenberg F, Del Junco D, Weyland B, Faucett W, Schmidt D, Rose E, et al. The effect of gestational age on the detection of Down syndrome by maternal serum alpha-fetoprotein screening. Am J Obstet Gynecol 1991; 165: 1396-403
3. Bishop J, Dunstan FDJ, Nix BJ, Reynolds TM. The effects of gestation dating on the calculation of patient specific risks in Down's syndrome screening. Ann Clin Biochem 1995; 32: 464-77
4. Cuckle H, Wald N, Thompson S. Estimating a woman's risk of having a pregnancy associated with Down syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 387-102
5. Bishop J. Statistical Techniques Involved in Establishing Reference Ranges [PhD thesis]. Cardiff: University of Wales, 1995
6. Wald N, Cuckle H, Densem J, Kennard A, Smith D. Maternal serum screening for Down's syndrome: The effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight. Br J Obstet Gynaecol 1992; 99: 144-9
7. Spencer K, Coombes K, Mallard A, Ward A. Free beta human choriogonadotrophin in Down's syndrome screening: A multicentre study of its role compared with other biochemical markers. Ann Clin Biochem 1992; 29: 506-18
8. Ryall RG, Staples AJ, Robertson EF, Pollard AC. Improved performance in a prenatal screening program for Down's syndrome incorporating serum free HCG subunit analyses. Prenat Diagn 1992; 12: 251-61
9. Crossley JA, Aitken DA, Connor JM. Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha-fetoprotein and age. Prenat Diagn 1991; 113: 83-101
10. Heyl PS, Miller W, Canick JA. Maternal serum screening for aneuploid pregnancy by alpha-fetoprotein, hCG and unconjugated estriol. Obstet Gynecol 1990; 76: 1025-31
11. Mardia KV, Kent JT, Bibby JM. Multivariate Analysis. London: Academic Press, 1979
12. Cuckle H. Risk estimation in Down's syndrome screening policy and practice. In: Grudzinskas J, Chard T, Chapman M, Cuckle H, eds. Proceedings of the 4th Conference on Endocrinology and Metabolism in Human Reproduction: Screening for Down Syndrome. Cambridge: University Press, 1994
13. Bishop J, Dunstan F, Nix B, Reynolds T, Swift A. All MoMs are not equal: Some statistical properties associated with reporting results in the form of multiples of the median. Am J Hum Genet 1993; 52: 425-30
14. Bishop JC, Dunstan FDJ, Nix BJ. Down syndrome screening: equal risks for all? Br J Obstet Gynaecol 1996; 103: 392